DiObex, Inc. To Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Posted on: Thursday, 25 October 2007, 09:00 CDT
SAN FRANCISCO, Oct. 25 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that Keith A. Vendola, MD, Head of Corporate Development, will deliver a corporate presentation at the upcoming Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York, New York. The DiObex presentation will take place on Monday, November 5 at 4:25 p.m. at the New York Palace Hotel in the Hubbard Room.
About DiObex
DiObex, Inc. is a San Francisco-based biotechnology company founded to develop novel products for the treatment of metabolic diseases. DiObex has two product candidates in Phase 2 clinical development. DIO-901 (very low dose glucagon) is in development as an extended release subcutaneous formulation for reducing or preventing insulin-induced hypoglycemia in type 1 diabetes mellitus. DIO-901 has received Fast Track status from the Food and Drug Administration. DIO-902 (levdexketoconazole) is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit http://www.diobex.com/.
DiObex, Inc.
CONTACT: Keith Vendola of DiObex, +1-415-551-4115, keith@diobex.com
Web site: http://www.diobex.com/
Source: PRNewswire
Related Articles
- New Potential Preventative Therapy For Type 1 Diabetes
- Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization
- TolerRx Receives Orphan Drug Designation From FDA for TRX4 for the Treatment of New-Onset Type 1 Diabetes
- Stress slows sugar metabolism in type 1 diabetics
- Contributions of Basal and Post-Prandial Hyperglycaemia to Micro- and Macrovascular Complications in People With Type 2 Diabetes
- Strategies to Prevent Type 2 Diabetes
- Thirty Years of Investigating the Autoimmune Basis for Type 1 Diabetes: Why Can't We Prevent or Reverse This Disease?
- Joslin Diabetes Center Announces New Nutrition Guidelines for People With Type 2 Diabetes or Pre-Diabetes Who Are Overweight or Obese
- Glycemic and Lipid Control in Hospitalized Type 2 Diabetic Patients: Evaluation of 2 Enteral Nutrition Formulas (Low Carbohydrate-High Monounsaturated Fat Vs High Carbohydrate)
- Comparing the Long-Term Cost-Effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients With Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds